Capmaxen 200 mg (Capmatinib): Uses, Dosage, Side Effects & Lung Cancer Treatment
Capmaxen 200 mg (Capmatinib): Uses, Dosage, Side Effects & Lung Cancer Treatment
What Is Capmaxen 200 mg?
Capmaxen 200 mg contains capmatinib, a targeted anticancer medicine belonging to the class of receptor tyrosine kinase inhibitors. It is specifically designed to interfere with abnormal signalling through the MET pathway, which can contribute to the growth and survival of certain cancer cells.
Capmatinib is particularly relevant to adults with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours contain a genetic alteration resulting in MET exon 14 skipping (METex14). Before treatment, appropriate molecular testing is required to identify patients whose tumours carry this alteration.
Unlike conventional chemotherapy, capmatinib is a targeted therapy. Its activity is directed toward a specific molecular abnormality rather than broadly attacking rapidly dividing cells.
The MET pathway normally plays a role in cell growth, movement and survival. When MET signalling becomes abnormally activated, it can contribute to uncontrolled cancer-cell behaviour. METex14 skipping can produce an abnormal MET protein with increased stability and prolonged signalling activity.
Capmatinib binds to the MET receptor tyrosine kinase and inhibits its activity. This can interfere with downstream signalling that supports cancer-cell proliferation and survival.
Capmaxen 200 mg should therefore be considered a specialized oncology medicine, rather than a general lung-cancer treatment. Its use depends on molecular testing, cancer stage, previous treatment and the patient's overall clinical condition.
What Is Capmatinib Used For?
Capmatinib is used for selected adults with advanced or metastatic non-small cell lung cancer containing a MET exon 14 skipping alteration.
The FDA indication is for adult patients with metastatic NSCLC whose tumours have a mutation leading to MET exon 14 skipping, confirmed through an appropriate FDA-approved test.
The EMA describes its approved use as monotherapy for adults with advanced NSCLC harbouring alterations leading to METex14 skipping who require systemic treatment following previous immunotherapy and/or platinum-based chemotherapy.
Key Treatment Area
Capmatinib may therefore be relevant when:
- The patient has advanced NSCLC.
- Molecular testing identifies a METex14 skipping alteration.
- The patient meets the applicable regulatory treatment criteria.
- The treating oncologist considers targeted MET inhibition appropriate.
Understanding MET Exon 14 Skipping
To understand why capmatinib is used, it is helpful to understand the MET gene and MET protein.
The MET gene contains different coding regions called exons. In some cancers, a genetic alteration causes exon 14 to be skipped during RNA processing.
This can result in a shortened MET receptor that remains active for longer than normal.
The consequence can be:
METex14 alteration → abnormal MET receptor → prolonged MET signalling → increased tumour-cell growth and survival
This molecular abnormality can act as a driver of cancer progression in a subset of NSCLC patients.
Capmatinib is designed to inhibit this abnormal MET signalling pathway.
How Does Capmatinib Work?
Capmatinib is a selective MET receptor tyrosine kinase inhibitor.
The MET receptor is involved in signalling processes that regulate:
- Cell growth
- Cell survival
- Cell movement
- Cellular proliferation
- Tissue development
In METex14-positive cancer, abnormal MET signalling may remain active for longer than normal.
Capmatinib binds to the MET receptor and inhibits its kinase activity. This reduces MET phosphorylation and interferes with downstream signalling pathways that support the growth and survival of MET-dependent cancer cells.
A simplified pathway is:
METex14 alteration → abnormal MET activity → cancer-cell signalling → tumour growth
Capmatinib acts at the MET signalling stage:
Capmatinib → MET inhibition → reduced downstream signalling → reduced cancer-cell growth and survival
This molecularly targeted mechanism differentiates capmatinib from traditional chemotherapy.
Capmatinib Dosage & Administration
The FDA-recommended dose of capmatinib is 400 mg orally twice daily, with or without food.
The EMA also lists 400 mg twice daily as the recommended dose for the authorised Tabrecta formulation.
Important Note About Capmaxen 200 mg
The presence of a 200 mg tablet strength does not mean that 200 mg once daily is the standard treatment dose.
For an adult receiving the standard 400 mg twice-daily regimen, the prescribed amount may involve multiple 200 mg tablets per dose. The exact regimen must always follow the patient's prescription.
Administration Guidance
Patients should:
- Take capmatinib exactly as prescribed.
- Take doses at approximately consistent times each day.
- Swallow the tablets whole.
- Do not crush, break or chew tablets unless specifically instructed.
- Take with or without food according to the applicable product information.
- Do not change the dose independently.
Missed Dose
If a dose is missed or vomiting occurs after taking a dose, the FDA prescribing information advises not to make up the missed dose and to take the next dose at its scheduled time.
Common Side Effects of Capmatinib
Capmatinib can cause adverse reactions. The frequency and severity can vary between patients.
Commonly reported effects include:
- Peripheral edema
- Nausea
- Fatigue
- Vomiting
- Reduced appetite
- Shortness of breath
- Back pain
- Increased blood creatinine
- Changes in liver enzymes
The EMA identifies peripheral edema, nausea, fatigue, increased creatinine, vomiting, dyspnea, decreased appetite and back pain among the common adverse effects.
Serious Side Effects
Some adverse reactions require urgent medical evaluation.
Interstitial Lung Disease / Pneumonitis
Capmatinib can cause interstitial lung disease or pneumonitis, potentially serious inflammatory conditions affecting the lungs.
Patients should promptly report:
- New cough
- Worsening cough
- Shortness of breath
- Difficulty breathing
- Unexplained respiratory symptoms
The FDA recommends monitoring for new or worsening pulmonary symptoms and permanent discontinuation if ILD/pneumonitis is confirmed.
Liver Toxicity
Capmatinib can cause elevations in liver enzymes and clinically significant hepatotoxicity.
Liver-function tests may therefore be required during treatment.
Pancreatic Toxicity
Changes in amylase and lipase can occur and may indicate pancreatic injury.
Appropriate laboratory monitoring may be required.
Hypersensitivity
Serious hypersensitivity reactions can occur. Symptoms such as facial swelling, severe rash, breathing difficulty or other signs of an allergic reaction require immediate medical attention.
Drug Interactions
Capmatinib can interact with other medicines and substances.
Patients should tell their healthcare provider about every medicine they use, including:
- Prescription medicines
- Over-the-counter medicines
- Herbal products
- Vitamins
- Supplements
- Traditional medicines
Some medicines can alter capmatinib exposure, while capmatinib can also affect the exposure of certain other medicines.
Because interaction management depends on the specific medicine involved, patients should not begin or stop another prescription or supplement without discussing it with their healthcare professional.
Warnings and Precautions
Lung Health
Patients with pre-existing pulmonary conditions should discuss their medical history with their oncology team.
New respiratory symptoms should be evaluated promptly because ILD/pneumonitis is an important safety concern.
Liver Function
Liver enzyme monitoring is important because capmatinib may cause hepatotoxicity.
Doctors may interrupt, reduce or permanently discontinue treatment depending on the severity of liver abnormalities.
Pancreatic Function
Amylase and lipase may be monitored because pancreatic toxicity has been reported.
Photosensitivity
Capmatinib can increase sensitivity to ultraviolet radiation. Patients should take appropriate precautions to limit excessive direct UV exposure.
Pregnancy and Breastfeeding
Capmatinib may cause fetal harm. Patients who are pregnant or planning pregnancy should discuss the potential risks and benefits of treatment with their healthcare professional.
Women who could become pregnant should follow the contraception recommendations provided by their treating physician.
Breastfeeding should be discussed with the oncology team before treatment and during therapy because the safety of breastfeeding while receiving capmatinib needs to be considered carefully.
Special Populations
Elderly Patients
Age alone does not necessarily prevent capmatinib treatment. However, older adults may have additional medical conditions or medicines that require closer monitoring.
Pediatric Patients
Capmatinib is primarily used in adult oncology according to current approved indications. Pediatric use should only occur under specialist medical supervision and an applicable approved indication.
Renal Impairment
Patients with kidney impairment should inform their healthcare professional before treatment. Renal function and other relevant laboratory findings may influence clinical management.
Hepatic Impairment
Liver function is particularly important because capmatinib can cause hepatotoxicity. Patients with existing hepatic impairment require individualized medical assessment.
Capmatinib and Lung Cancer Treatment
Capmatinib represents an important example of precision oncology.
Traditional cancer treatment often relies on tumour type and stage. Targeted therapy adds another layer by examining the molecular characteristics of the cancer.
For patients whose NSCLC contains a MET exon 14 skipping alteration, identifying the molecular abnormality can help clinicians determine whether MET-targeted treatment is appropriate.
This approach can be summarized as:
Cancer diagnosis → Molecular testing → METex14 identification → Targeted treatment consideration → Clinical monitoring
The EMA notes that testing for METex14 skipping should be performed before treatment.
Frequently Asked Questions
1. What is Capmaxen 200 mg?
Capmaxen 200 mg contains capmatinib, a targeted MET tyrosine kinase inhibitor used in selected adults with METex14-positive NSCLC.
2. What is capmatinib used for?
Capmatinib is used for adults with advanced or metastatic NSCLC whose tumours contain a mutation causing MET exon 14 skipping, subject to applicable regulatory criteria.
3. Is capmatinib a chemotherapy medicine?
No. Capmatinib is a targeted kinase inhibitor rather than conventional cytotoxic chemotherapy.
4. How does capmatinib work?
It inhibits the MET receptor tyrosine kinase, interfering with abnormal MET signalling that can promote cancer-cell growth and survival.
5. What is MET exon 14 skipping?
It is a genetic alteration that can produce an abnormal MET receptor with prolonged signalling activity and may act as a cancer-driving alteration in some NSCLC patients.
6. What is the usual capmatinib dose?
The FDA and EMA list 400 mg twice daily for the relevant authorised capmatinib formulation.
7. Is Capmaxen 200 mg taken once a day?
The 200 mg strength should not be confused with the standard dosing schedule. The prescribed regimen must be determined by the oncologist.
8. Can capmatinib be taken with food?
The FDA prescribing information allows capmatinib to be taken with or without food.
9. What are the common side effects of capmatinib?
Common effects include swelling, nausea, fatigue, vomiting, decreased appetite, breathing difficulty, back pain and increased creatinine.
10. Can capmatinib affect the lungs?
Yes. Interstitial lung disease and pneumonitis are important potential adverse reactions and new respiratory symptoms require prompt evaluation.
11. Can capmatinib affect the liver?
Yes. Capmatinib may increase liver enzymes and can cause hepatotoxicity, so liver-function monitoring may be required.
12. Does capmatinib work for all lung cancer patients?
No. It is specifically targeted toward patients whose cancer has the relevant MET exon 14 skipping alteration and who meet the applicable treatment criteria.
13. Is molecular testing required before capmatinib?
Yes. Patient selection is based on identification of the relevant MET exon 14 skipping alteration using an appropriate diagnostic test.
14. Can capmatinib cure lung cancer?
It should not be described as a guaranteed cure. It is a targeted treatment intended for appropriately selected patients with advanced/metastatic NSCLC.
15. Who should prescribe capmatinib?
Capmatinib should be prescribed and monitored by a qualified healthcare professional experienced in cancer treatment.
Global Medicine Information & Support by RootAid Pharma
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides information and support relating to prescription and specialty medicines for patients and organizations seeking international pharmaceutical information.
Our educational resources can cover:
- Oncology medicines
- Targeted cancer therapies
- Lung cancer treatments
- Precision oncology
- Molecularly targeted medicines
- Specialty prescription medicines
- International medicine information
RootAid Pharma does not claim to manufacture Capmaxen 200 mg or capmatinib. Availability, prescription requirements, import rules and regulatory conditions can vary by country.
Medical Disclaimer
This article is provided for general educational purposes and is not a substitute for medical diagnosis, professional advice or individualized cancer treatment.
Capmatinib is a prescription oncology medicine. Treatment selection requires appropriate molecular testing and professional assessment. Dosage, treatment duration and dose modifications should be determined by the treating healthcare professional.
Do not start, stop, or change capmatinib treatment without medical supervision.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.